Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.33 |
| ▸ | NOS3 | P29474 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7465174 | 0.73 | NOS1 (0.32) | NOS1NOS3NOS2 | |
| SCHEMBL29383163 | 0.72 | NOS1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL1670886 | 0.72 | NOS1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL8173271 | 0.67 | NOS1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL4938 | 0.62 | NOS1 (0.32) | NOS1NOS3NOS2 | |
| SCHEMBL4409993 | 0.55 | MEN1 (0.32) | — | |
| SCHEMBL28886119 | 0.55 | NOS1 (0.42) | NOS1NOS3NOS2 | |
| SCHEMBL30353880 | 0.53 | MEN1 (0.35) | — | |
| SCHEMBL8069320 | 0.53 | MEN1 (0.35) | — | |
| SCHEMBL1723946 | 0.53 | NOS1 (0.46) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | claimed |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-07 | — | — | US | disclosed |
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-22 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3854796-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM | Children's Hospital Medical Center (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3500571-B1 | IMIDAZO[1,2-A]PYRIDIN COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM | CHILDRENS HOSPITAL MED CT (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200270242-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-08-27 | — | — | US | disclosed |
| US-20200199123-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | CHILDRENS HOSPITAL MED CT (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3500571-A2 | IMIDAZO[1,2-A]PYRIDIN COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM | Children's Hospital Medical Center (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-1995007257-A1 | DIFLUORO STATONE ANTIVIRAL ANALOGS | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0409676-B1 | Novel acetylcholinesterase inhibitors | MERRELL DOW PHARMA (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1995001958-A1 | DIFLUORO STATONE ANALOGS | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-19 | — | — | WO | disclosed |
| WO-1994029255-A1 | AROMATIC ACETYLCHOLINESTERASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| EP-0627400-A1 | Aromatic acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0611769-A1 | Silylated acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0291787-B1 | Novel substituted silyl alkylene amines | MERRELL DOW PHARMA (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0409676-A1 | Novel acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0403713-A1 | Novel acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-12-27 | — | — | EP | disclosed |
| EP-0291787-A1 | Novel substituted silyl alkylene amines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199123-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | IRAK1, IRAK2, IRAK3 | NOS1 4013/4885NOS3 4244/4885NOS2 3937/4885 |
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | IRAK1, IRAK4, FLT3 | NOS1 2022/4885NOS3 2726/4885NOS2 2566/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | NOS1 4059/4885NOS3 4318/4885NOS2 3284/4885 |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | IRAK1, IRAK4, FLT3 | NOS1 2616/4885NOS3 3122/4885NOS2 2899/4885 |
| US-20200270242-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | VHL, ETV6, C5 | NOS1 3825/4885NOS3 4078/4885NOS2 3111/4885 |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | IRAK1, IRAK4, IRAK2 | NOS1 3321/4885NOS3 3752/4885NOS2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.